AACR 2024 Poster 7174

Pharmacokinetics and Immunogenicity/ADA of anti-PD-1 Antibody in Humanized FcRn Mouse Models Compared to Immunocompetent Mouse Models

Xiaolong Tu, Xinhe Feng, Weifang Wang, Xunhua Ding, Dong Huang, Ludovic Bourre, Xiaobo Chen

Navigating the complexities of therapeutic antibody development in cancer therapy, this study highlights the significance of the hFcRn transgenic mouse model in obtaining more human-representative PK data. By comparing the PK and immunogenicity profiles of an anti-PD-1 antibody in hFcRn mice versus wild-type counterparts, our research underlines the model's utility in refining preclinical assessments of antibody-based treatments. This work lays the groundwork for more accurate, predictive evaluations of drug safety and efficacy, facilitating the selection of safer starting doses for first-in-human studies.

Download this Poster to Discover:

• Enhanced predictive pharmacokinetics in hFcRn mice, mirroring human data more closely.
• Lower antibody immunogenicity in hFcRn mice, pointing to improved preclinical evaluation.
• The hFcRn model's potential to accelerate the development of effective cancer therapies.

Download the Poster Now!